Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

Completed · Phase 2 · Has a placebo group

Conditions studied: Dyslipidemias, High Cholesterol, Hypercholesterolemia

In brief

This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.

Key facts

Study ID
NCT05266586
Run by
NewAmsterdam Pharma
People needed
119
Starts
2022-03-09
Expected to finish
2022-09-08
Last updated by the study team
2024-07-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.